Who
Jon Congleton
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Mineralys Therapeutics; Director, Immunic; Director, Avalyn Pharma; President and CEO, Nivalis Therapeutics.
In numbers
- Trades disclosed
- 64
- Buys
- 8
- Sells
- 19
- Bought
- $208K
- Sold
- $24.5M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 11 Sep 2015
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.9M75,000 at $25.46 | filing |
| 13 Jul 2026filed 15 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $291K10,700 at $27.24 | filing |
| 13 Jul 2026filed 15 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $291K10,700 at $27.24 | filing |
| 5 Jul 2026filed 7 Jul 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,370 at $0.00 | filing |
| 5 Jul 2026filed 7 Jul 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,370 at $0.00 | filing |
| 30 Jun 2026filed 30 Jun 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.5M58,000 at $25.94 | filing |
| 30 Jun 2026filed 30 Jun 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $456K17,000 at $26.82 | filing |
| 30 Jun 2026filed 30 Jun 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.5M58,000 at $25.94 | filing |
| 30 Jun 2026filed 30 Jun 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $456K17,000 at $26.82 | filing |
| 29 Jun 2026filed 29 Jun 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,740 at $0.00 | filing |
| 29 Jun 2026filed 29 Jun 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,740 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,978 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,978 at $0.00 | filing |
| 13 Apr 2026filed 15 Apr 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $422K15,730 at $26.83 | filing |
| 13 Apr 2026filed 15 Apr 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $422K15,730 at $26.83 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $494K19,364 at $25.50 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.5M55,183 at $26.54 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K453 at $27.05 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $494K19,364 at $25.50 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.5M55,183 at $26.54 | filing |
News
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026MLYS · manilatimes.net · 22 Oct 2026Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel CoatsMLYS · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Jon Congleton; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.